key: cord-0913804-xh1iw8gf
authors: Zhang, Tongyue; Liu, Danfei; Tian, Dean; Xia, Limin
title: The roles of nausea and vomiting in COVID-19: did we miss something?
date: 2020-10-17
journal: J Microbiol Immunol Infect
DOI: 10.1016/j.jmii.2020.10.005
sha: 70bbd37500f50826c3d01663916499b3b47c4c00
doc_id: 913804
cord_uid: xh1iw8gf

The Coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is an international public health emergency. Although respiratory symptoms predominate the clinical manifestations of COVID-19, gastrointestinal symptoms have been observed in a subset of patients. Notably, some patients have nausea/vomiting as the first clinical manifestation of COVID-19, which is often overlooked by people. It is now clear that not only the lungs, the gastrointestinal tract could also be attacked by SARS-CoV-2. Its host receptor angiotensin-converting enzyme 2 (ACE2), which acts as a gateway to infection, was found to be highly expressed in the gastrointestinal epithelium and may lead to the development of nausea/vomiting. Raise awareness of these symptoms and take timely intervention would help people combat the pandemic. This review discussed epidemiology, mechanisms, management, and prevention of COVID-19 related nausea and vomiting.

The Coronavirus disease 2019 pandemic, caused by severe acute 20 respiratory syndrome coronavirus 2 (SARS-CoV-2), has brought considerable morbidity and 21 mortality since late December 2019 and continues threatening the whole world. As of 22

September 6, 2020, more than 25 million confirmed cases and more than 876,616 deaths had 23 been reported worldwide. 1 24 SARS-CoV-2, an enveloped positive-sense, single-stranded RNA virus, belongs to the 25 Sarbecovirus subgenus, along with SARS-CoV. 2 The SARS-CoV-2 receptor is the 26 angiotensin-converting enzyme 2 (ACE2) whose binding affinity for SARS-CoV-2 is 10~20 27 times higher than that for 4 It is reported that ACE2 is abundantly expressed not 28 only in lung alveolar type 2 cells and esophageal cells, but also on cells in gastrointestinal 29 tract, including glandular cells of gastric, duodenal and rectal, absorptive enterocytes from the 30 ileum and colon, making these tissues susceptible to infection by the virus. 5, 6 In the meantime, 31 a growing number of studies have reported gastrointestinal symptoms in patients with 32 COVID-19. Moreover, patients with gastrointestinal involvement had a higher prevalence of 33 any CT imaging features of COVID-19 pneumonia. These findings indicate that the 82 symptoms of COVID-19 can be atypical. Meanwhile, nausea and vomiting should not be 83 overlooked, especially for those who live in high-risk areas. 84

Conflicting results about nausea and vomiting in severe and non-severe cases have been 85

reported. Yan et al. found that there was no significant difference in nausea/vomiting between 86 severe and non-severe patients (nausea 8.3% vs 4.5%; vomiting 2.3% vs 11.1%). 30 Another 87 study reported similar results: the incidence rates of nausea/vomiting between ICU patients 88 and non-ICU patients were not statistically different. 13 On the contrary, Chen et al. reported 89 that nausea and vomiting were more common in mild group. 31 Similarly, Zhang et al. reported 90 that the proportion of nausea in non-severe patients (23.2%) was significantly higher than that 91 in severe patients (8.8%). 32 92

Of note, it is quite challenging to compare the rates of nausea and vomiting between 93 studies. The definitions of nausea and vomiting are relatively vague and subjective. 33 There 94 are no objective data or images to confirm the judgment. Since we lack precise diagnostic 95 criteria for nausea and vomiting, it mainly depends on the patients' subjective feelings to 96 judge and to evaluate these symptoms, which may be inaccurate due to memory bias and 97 individual tolerance. 34 Moreover, criteria for diagnosing nausea and vomiting may be 98 inconsistent among hospitals, which may affect the final diagnosis by clinicians. 35 In 99 summary, the differences in the incidence of nausea and vomiting between studies were partly 100 attributable to subjective factors.

Although the specific mechanisms involved in COVID -19 associated nausea and 105 vomiting are not entirely known, some theories of the viral infection could explain this 106 phenomenon (Fig.1) . 107

3.1 ACE2-mediated direct SARS-CoV-2 invasion of gastrointestinal epithelium 108 ACE2, the functional receptor of SARS-CoV-2, facilitates viral entry into the host's 109 cells. 36 Meanwhile, as a vital metalloproteinase, ACE2 could convert angiotensin II (Ang II) 110

to angiotensin-(1-7), leading to protective effects on tissues such as anti-inflammation, 111

anti-oxidant, and so on. 37 112 SARS-CoV-2 spike (S) protein binds to ACE2 and in concert with host cell proteases 113 transmembrane serine protease 2 (TMPRSS2), which plays a crucial role cleaving S protein, 114 to invade the cells. 36 In a single-cell transcriptomic analysis, ACE2 and TMPRSS2 were 115 highly expressed in gastrointestinal tract epithelium. 6 Using confocal-and 116 electron-microscopy, Lamers et al. observed that SARS-CoV-2 could productively infect 117 human gut enterocytes. 3 They also found that low levels of ACE2 may be sufficient for viral 118 entry. It is reported that SARS-CoV-2 was localized in the cytoplasm of gastric, duodenal, and 119 rectum glandular epithelial cells. 5 These findings suggest that SARS-CoV-2 can actively 120 invade the gastrointestinal tract, which highly expresses ACE2. 121 If the immune system cannot defeat the infection, then SARS-CoV-2 will actively 122 replicate. The massive replication of the virus will decrease the level of ACE2 and destroy the 123 host's cells. In the meantime, downregulation of ACE2 leads to decreased organ protection. 38 124

As a result, the gastrointestinal function is ruined and inflammation is accelerated. 125

Therefore, nausea and vomiting may be caused by the virus attacking the gastrointestinal 126 tract. 

Some patients with COVID-19 presented with nausea and vomiting during 147 hospitalization, which may be related to the adverse effects of treatments. After receiving 148 remdesivir, 2 of the first 7 patients hospitalized with COVID-19 showed nausea, which had 149 not been observed before the application. 43 One randomized, controlled trial conducted by 150

Cao et al. included 199 hospitalized patients with severe COVID-19, of which 99 received 151 treatment to lopinavir/ritonavir and 100 to the standard-care group for 14 days. 44 There were 152 9.5% (9/99) with nausea and 6.3% (6/99) with vomiting, while there was no one who had 153 nausea/vomiting in the standard-care group. Gastrointestinal adverse events were the most 154 common ones and were the primary reason for discontinuing the full 14-day course. 155

Anxiety and stress, psychological distress brought by COVID-19, are of concern 157 worldwide lately, which are also common causes of nausea and vomiting. 33 Underneath the 158 medical crisis, long-term social isolation and the economic burden, people remain at high risk 159 of having mental health problems, especially for the vulnerable ones such as healthcare 160 workers, children and the elderly. 45 National surveys reveal a high prevalence of distress in 161 the population during COVID-19, which is 35%~60%. 45 A study including 1210 respondents 162 from 194 cities in China showed that 28.8% reported moderate to severe anxiety symptoms. 46 163

A prospective case-control study from the United States showed that among the outpatients 164 during the COVID-19 pandemic, nausea and vomiting are common in outpatients who tested 165 negative for COVID-19:26% and 12% respectively. 47 While there is yet no specific data of 166 nausea and vomiting in people with anxiety, psychological factors do play an important role in 167

people's illness and should be regarded with certain care during the COVID-19 pandemic. clinical trials to confirm. 49-51 Therefore, the current key measures lie in prevention, 188 monitoring and timely intervention. 52 The best way to protect people from infection is to 189 avoid being exposed to SARS-CoV-2. Moreover, during COVID-19, for those who are under 190 great pressure, for example, workers in health and long-term care, timely psychological 191 support is essential. 45 192 193 

The ongoing COVID-19 pandemic requires long-term vigilance and strategies for 

WHO. WHO coronavirus disease (COVID-19) dashboard. Accessed

A Novel Coronavirus from Patients with 38

ACE2: The key Molecule for Understanding the Pathophysiology of 309 Severe and Critical Conditions of COVID-19: Demon or Angel?

SnapShot: COVID-19

Cytokine release syndrome

Respiratory virus infections: UnderstandingCOVID-19

Diarrhea and altered inflammatory cytokine 319 pattern in severe coronavirus disease 2019: Impact on disease course and in-hospital mortality

First 12 patients with 322 coronavirus disease 2019 (COVID-19) in the United States

A Trial of Lopinavir-Ritonavir in Adults 325 Hospitalized with Severe Covid-19

UNITED NATIONS POLICY BRIEF: COVID-19 AND THE NEED FOR ACTION ON MENTAL 328 HEALTH

Are Gastrointestinal Symptoms 335 Specific for COVID-19 Infection? A Prospective Case-Control Study from the United States

Safety and 340 immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 341 1/2, single-blind, randomised controlled trial

Safety, tolerability, and 344 immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, 345 open-label, non-randomised, first-in-human trial

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 349 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

COVID-19: towards understanding of pathogenesis